MAPK7 and cancer: BRD4inhibitors and ERK5-BRD4 dual inhibitors both demonstrated antiproliferativeactivity in this model, whereas the ERK5-selective inhibitor did not.This data suggests that inhibition of ERK5 kinase activity may notbe sufficient or necessary to affect cancer cell proliferation andviability.